86 related articles for article (PubMed ID: 14979613)
1. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system.
Haehner T; Refaie MO; Müller-Enoch D
Arzneimittelforschung; 2004; 54(1):78-83. PubMed ID: 14979613
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
Rodrigues AD; Mulford DJ; Lee RD; Surber BW; Kukulka MJ; Ferrero JL; Thomas SB; Shet MS; Estabrook RW
Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
4. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
Satoh T; Fujita KI; Munakata H; Itoh S; Nakamura K; Kamataki T; Itoh S; Yoshizawa I
Anal Biochem; 2000 Nov; 286(2):179-86. PubMed ID: 11067738
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the role of cytochrome b5 and divalent cations in the maximal nifedipine oxidase activity of human liver.
Müller-Enoch D
Arzneimittelforschung; 1999 May; 49(5):470-5. PubMed ID: 10367111
[TBL] [Abstract][Full Text] [Related]
6. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
Zhang Y; Guo X; Lin ET; Benet LZ
Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
9. Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase.
Kousba A; Soll R; Yee S; Martin M
Drug Metab Dispos; 2007 Dec; 35(12):2242-51. PubMed ID: 17881660
[TBL] [Abstract][Full Text] [Related]
10. Antiprogestin-mediated inactivation of cytochrome P450 3A4.
Jang GR; Benet LZ
Pharmacology; 1998 Mar; 56(3):150-7. PubMed ID: 9532615
[TBL] [Abstract][Full Text] [Related]
11. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.
Baumhäkel M; Kasel D; Rao-Schymanski RA; Böcker R; Beckurts KT; Zaigler M; Barthold D; Fuhr U
Int J Clin Pharmacol Ther; 2001 Dec; 39(12):517-28. PubMed ID: 11770832
[TBL] [Abstract][Full Text] [Related]
12. The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein.
Shet MS; Faulkner KM; Holmans PL; Fisher CW; Estabrook RW
Arch Biochem Biophys; 1995 Apr; 318(2):314-21. PubMed ID: 7733659
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.
Lampen A; Christians U; Guengerich FP; Watkins PB; Kolars JC; Bader A; Gonschior AK; Dralle H; Hackbarth I; Sewing KF
Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characteristics of purified beef liver NADPH-cytochrome P450 reductase.
Arinç E; Celik H
J Biochem Mol Toxicol; 2002; 16(6):286-97. PubMed ID: 12481304
[TBL] [Abstract][Full Text] [Related]
15. High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge.
Ingelman-Sundberg M; Hagbjörk AL; Ueng YF; Yamazaki H; Guengerich FP
Biochem Biophys Res Commun; 1996 Apr; 221(2):318-22. PubMed ID: 8619853
[TBL] [Abstract][Full Text] [Related]
16. Effects of an immunosuppressive agent, tacrolimus (FK-506), on the activities of cytochrome P-450-linked monooxygenase systems in rat liver microsomes.
Izuishi K; Wakabayashi H; Ohnishi T; Maeta H; Maeba T; Ichikawa Y
Int J Biochem Cell Biol; 1997 Jun; 29(6):921-8. PubMed ID: 9304807
[TBL] [Abstract][Full Text] [Related]
17. Catalyzation of cocaine N-demethylation by cytochromes P4502B, P4503A, and P4502D in fish liver.
Arinç E; Bozcaarmutlu A
J Biochem Mol Toxicol; 2003; 17(3):169-76. PubMed ID: 12815613
[TBL] [Abstract][Full Text] [Related]
18. Complexation of membrane-bound enzyme systems.
Müller-Enoch D; Gruler H
Z Naturforsch C J Biosci; 2000; 55(9-10):747-52. PubMed ID: 11098825
[TBL] [Abstract][Full Text] [Related]
19. Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes.
Gan L; von Moltke LL; Trepanier LA; Harmatz JS; Greenblatt DJ; Court MH
Drug Metab Dispos; 2009 Jan; 37(1):90-6. PubMed ID: 18838505
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
